Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 12421819
Mai H, et al. (2003) A functional role for nicotine in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 278, 1886-91 12421819
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

T69-p - Bcl-2 (human)
Modsite: SRDPVARtsPLQtPA SwissProt Entrez-Gene
Orthologous residues
Bcl‑2 (human): T69‑p, Bcl‑2 (mouse): T69‑p, Bcl‑2 (rat): T69‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Disease tissue studied:  lung cancer, small-cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H82 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nicotine no change compared to control

S70-p - Bcl-2 (human)
Modsite: RDPVARtsPLQtPAA SwissProt Entrez-Gene
Orthologous residues
Bcl‑2 (human): S70‑p, Bcl‑2 (mouse): S70‑p, Bcl‑2 (rat): S70‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Disease tissue studied:  lung cancer, small-cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H82 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nicotine increase
staurosporine nicotine inhibit treatment-induced increase
PD98059 nicotine inhibit treatment-induced increase
ET18OCH3 nicotine inhibit treatment-induced increase
SB202190 nicotine no effect upon treatment-induced increase
hexamethionium nicotine no effect upon treatment-induced increase
Downstream Regulation
Effect of modification (function):  molecular association, regulation
Effect of modification (process):  apoptosis, inhibited
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
BAX (human) Induces co-immunoprecipitation

S87-p - Bcl-2 (human)
Modsite: AAAGPALsPVPPVVH SwissProt Entrez-Gene
Orthologous residues
Bcl‑2 (human): S87‑p, Bcl‑2 (mouse): S84‑p, Bcl‑2 (rat): S84‑p
Characterization
Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
Disease tissue studied:  lung cancer, small-cell lung cancer
Relevant cell lines - cell types - tissues:  NCI-H82 (pulmonary)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
nicotine no change compared to control